The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

These factors together underpin the positive long-term outlook for 10x Genomics. Souda covers the Healthcare sector, focusing on stocks such as Revvity, Exact Sciences, and Natera. According to ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at ...

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...

"The entire department that I work with consist of very intelligent individuals that are great at their job. The best part is that every person in my department is kind and willing to teach me and ...